The risks of asymptomatic hyperuricaemia and the use of uricosuric diuretics.
Introduction of new uricosuric diuretics will be accompanied by the unknown risk factors associated with the use of any new drug, as demonstrated by reports of hepatic toxicity associated with ticrynafen. In addition to unexpected reactions, there are potential risks related to induction of uricosuria, which are serious and have been reported to occur. More importantly, the risk of developing clinical gout or coronary heart disease due to mild asymptomatic hyperuricaemia appears minimal, so indications for the use of uricosuric diuretics are limited. If a uricosuric diuretic is thought necessary (and is available), it would seem prudent to measure the daily excretion rate of uric acid to identify those patients with hyperuricaemia related to overproduction of uric acid. A uricosuric diuretic should be avoided in those patients, as well as in patients with uric acid stones, and possibly in those with calcium stones. A uricosuric diuretic might be useful for patients with hypertension who also have hyperuricaemia due to a low excretion of uric acid.
D003327:Coronary Disease / Q000209:etiology; D004232:Diuretics / Q000009:adverse effects*; D006801:Humans; D007669:Kidney Calculi / Q000209:etiology; D007674:Kidney Diseases / Q000209:etiology; D012306:Risk; D013989:Ticrynafen / Q000009:adverse effects; D014527:Uric Acid / Q000097:blood*; D014528:Uricosuric Agents / Q000009:adverse effects*
D004232:Diuretics; D014528:Uricosuric Agents; D014527:Uric Acid; D013989:Ticrynafen